Do Kim
Stock Analyst at Piper Sandler
(2.01)
# 3,064
Out of 5,122 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $78.97 | -20.22% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $37.68 | +22.08% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $453.74 | -34.76% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $123.18 | -9.08% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $17.80 | +388.76% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $1.60 | +1,337.50% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $42.83 | -53.30% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $9.82 | +337.88% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $44.04 | -27.34% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.45 | +537.68% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $43.62 | -56.44% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $8.94 | +78.97% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $397.25 | -53.43% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $5.50 | +16,263.64% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $67.70 | -48.30% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $0.98 | +1,934.17% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $78.97
Upside: -20.22%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $37.68
Upside: +22.08%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $453.74
Upside: -34.76%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $123.18
Upside: -9.08%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $17.80
Upside: +388.76%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $1.60
Upside: +1,337.50%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $42.83
Upside: -53.30%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $9.82
Upside: +337.88%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $44.04
Upside: -27.34%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.45
Upside: +537.68%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $43.62
Upside: -56.44%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $8.94
Upside: +78.97%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $397.25
Upside: -53.43%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $5.50
Upside: +16,263.64%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $67.70
Upside: -48.30%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $0.98
Upside: +1,934.17%